10-Q: Picard Medical Q3 2025: IPO Boosts Cash, Losses Persist

Picard Medical, Inc. reported increased revenue and a significant cash infusion from its recent IPO, but continued to post substantial net losses for the nine months ended September 30, 2025.

Summary

• Net loss for the nine months ended September 30, 2025, was $22.7 million, an 86% increase from $12.2 million in the same period of 2024.
• Total revenues increased by 11% to $3.9 million for the nine months ended September 30, 2025, compared to $3.6 million in 2024, driven by a 10% increase in product sales.
• The company completed its Initial Public Offering (IPO) on September 2, 2025, raising $17 million in gross proceeds, with an additional $2.6 million from an over-allotment option.
• Cash and cash equivalents significantly increased to $2.8 million as of September 30, 2025, from $96,000 at December 31, 2024, primarily due to IPO proceeds.
• All outstanding convertible notes and Series A-1 Preferred Stock were converted into common shares, eliminating $35.3 million in current liabilities and improving stockholders' equity from a deficit of $44.0 million to a positive $8.0 million.
• Material weaknesses in internal control over financial reporting persist, including lack of segregation of duties and formal review processes.

Sentiment

Score: 4

Explanation: The successful IPO and subsequent conversion of debt and preferred stock significantly improved the balance sheet and liquidity, which are strong positives. However, the substantial increase in net loss and gross loss, coupled with continued negative operating cash flow and acknowledged material weaknesses in internal controls, points to ongoing operational challenges and a high burn rate. The company's 'going concern' warning, even post-IPO, tempers the positive impact of the capital raise.

Positives

• Successful completion of Initial Public Offering (IPO) on September 2, 2025, raising $15.2 million net proceeds, plus an additional $2.35 million net from over-allotment.
• Significant increase in cash and cash equivalents to $2.813 million as of September 30, 2025, from $96,000 at December 31, 2024.
• Conversion of all outstanding convertible notes and Series A-1 Preferred Stock into common shares, reducing total liabilities from $35.8 million to $5.6 million and shifting stockholders' equity from a $44.0 million deficit to a positive $8.0 million.
• Total revenues increased by 11% to $3.931 million for the nine months ended September 30, 2025, compared to $3.555 million in the prior year, driven by a 10% increase in product sales.
• US product sales increased by $0.87 million for the nine months ended September 30, 2025.
• Issuance of a new U.S. Patent (No. 12,383,722 B2) in August 2025, covering core technology for the next-generation total artificial heart system, expanding the patent portfolio.
• Net loss per share improved to $(0.96) for the nine months ended September 30, 2025, from $(1.79) in the prior year, despite a higher net loss, due to increased share count.

Negatives

• Net loss increased by 86% to $22.711 million for the nine months ended September 30, 2025, compared to $12.217 million in the same period of 2024.
• Gross loss increased by 148% to $615,000 for the nine months ended September 30, 2025, from $248,000 in the prior year, with total cost of revenues increasing by 20% while total revenues only increased by 11%.
• Operating losses increased slightly by 1% to $10.254 million for the nine months ended September 30, 2025.
• Interest expense surged by 229% to $5.386 million for the nine months ended September 30, 2025.
• Derivative loss significantly increased by 1,496% to $7.040 million for the nine months ended September 30, 2025, primarily due to non-cash accounting for convertible notes.
• Net cash used in operating activities increased to $11.296 million for the nine months ended September 30, 2025, from $8.722 million in the prior year.
• The company continues to operate at a substantial loss and expects this to continue into the foreseeable future, requiring additional financing.
• International sales (Europe and Rest of the World) decreased by $0.35 million and $0.14 million, respectively, for the nine months ended September 30, 2025.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to historical operating losses and negative cash flows, and the expectation of continued losses in the foreseeable future.
• Need to raise additional debt and/or equity financing to fund operations until positive cash flows are generated, with no assurance of availability on favorable terms.
• Potential for dilution of current shareholders' ownership interest if additional capital is raised through equity sales.
• Debt and preferred equity financing may involve restrictive agreements that limit the company's actions.
• Risk of being required to delay, limit, reduce, or terminate parts of the strategic business plan or future commercialization efforts if sufficient financial resources are not obtained.
• Material weaknesses in internal control over financial reporting persist, including lack of segregation of duties, formal review processes, written policies, and controls over related party transactions, which could lead to material misstatements not being prevented or detected.
• Dependence on a single primary product, the SynCardia TAH, and its related components.
• Exposure to foreign currency translation adjustments, which resulted in a negative impact of $48,000 for the nine months ended September 30, 2025.
• Concentration of revenue with a few key customers (Customer A, C, E) and geographic regions (US, Serbia).
• Geopolitical factors, including the Russian invasion of Ukraine and the Israel-Hamas conflict, and the risk of global and regional economic downturns.
• Impact of pandemics or other national or international health-related events.
• Effects of inflation and changes in interest rates.
• Ability to retain or recruit executive and senior management and other key employees.
• Ability to manage growth effectively.
• Ability to achieve and maintain profitability in the future.
• Success of strategic relationships with third parties.
• Dependence on acquisitions for growth.
• Ability to develop new products and solutions, bring them to market in a timely manner, and make enhancements to the platform.
• Development, effects, and enforcement of laws and regulations.
• Inherent risks related to acquisitions and managing growth and changing business.
• Need for significant financial resources for growth and future profitability.
• Limited operating history.

Future Outlook

Management expects operating losses and negative cash flows from operations to continue into the foreseeable future, necessitating additional debt and/or equity financing. The company aims to scale up product and rental revenue to offset fixed overhead costs and is investing heavily in developing next-generation devices, including a portable driver, hospital driver, and fully implantable system. The IPO proceeds are expected to fund operations into 2025 based on current plans and macroeconomic conditions.

Management Comments

• Our long-term mission is to build a portfolio of medical technology companies active in the cardiovascular space.
• We intend to achieve this goal by acquiring, developing, or by in-licensing of promising technologies or assets with a focus on approved devices, or devices close to being approved.
• Our product development roadmap is focused on developing, manufacturing, and commercializing successive generations of the SynCardia TAH to further improve clinical outcomes, usability, and patient quality of life.
• We expect to incur significant costs to comply with corporate governance, internal controls, and similar requirements applicable to public companies.
• We expect to incur increased costs associated with establishing sales, marketing, and revenue growth.
• Management believes, based on a variety of factors, it is more likely than not that the deferred income tax assets will not be fully realized.
• Management continues to implement measures designed to ensure that control deficiencies contributing to the material weakness are remediated, such that these controls are designed, implemented, and operating effectively.

Industry Context

Picard Medical operates in the specialized and high-stakes cardiovascular medical technology sector, specifically with its FDA-approved SynCardia Total Artificial Heart (TAH), which is noted as the only commercially available TAH in the U.S. as a bridge to transplant. The company's focus on developing next-generation devices and expanding its patent portfolio aligns with broader industry trends towards innovation and improving patient outcomes in advanced heart failure. The challenges of scaling revenue to offset high fixed costs and the need for continuous capital infusion are common in the medical device industry, particularly for companies with complex, high-cost products and extensive R&D requirements. The planned joint venture in China indicates an intent to tap into emerging global markets for medical devices.

Comparison to Industry Standards

• The SynCardia TAH is highlighted as the only total artificial heart approved and commercially available in the United States as a bridge to heart transplant, distinguishing it from most other devices which are VADs (Ventricular Assist Devices). This unique market position suggests a high barrier to entry and limited direct competition for its specific product type.
• Over 2,100 SynCardia TAHs have been implanted in 27 countries globally, including major markets like the US, France, Germany, and the UK, indicating a significant global footprint for a specialized device.
• The company's continued operating losses and reliance on external financing are common for medical device companies in the R&D and early commercialization phases, especially those developing complex, high-cost technologies. However, the magnitude of the net loss increase (86%) and gross loss increase (148%) suggests significant operational inefficiencies or aggressive investment relative to revenue growth, which might be worse than industry averages for companies at a similar stage post-IPO.
• The identified material weaknesses in internal controls are a concern, as public companies are expected to have robust financial reporting controls. While not uncommon for newly public smaller reporting companies, remediation is critical for investor confidence and regulatory compliance.

Corporate Governance

Related Party Transactions

• PMI advanced $100,000 to Versa Capital Management, LLC (common ownership with Sindex, former owner of SynCardia) on September 27, 2021, under an unsecured promissory note accruing 8% interest. Balance receivable was $137,000 as of September 30, 2025.
• Various loans from Fang Family Fund, LLC and Fang Family Fund II, LLC (entities affiliated with former CEO and current director Richard Fang) totaling approximately $7.0 million were consolidated into one convertible note on July 2, 2024. This note was later donated by Richard Fang to Nexus Science Foundation Inc. and Another Dimension Foundation on November 12, 2024, and subsequently converted to common shares on September 2, 2025.
• Additional loans from Fang Family Fund II, LLC ($580,000, $110,000, $350,000, $450,000) were borrowed in July-September 2024 and repaid on September 4, 2025.
• The company determined it overpaid interest on Fang Family loans by $134,712, recognized as a receivable as of September 30, 2025.
• Senior Secured Notes totaling $1.75 million were borrowed from Fang Family Fund II, LLC in January and June 2025, bearing 6% interest, and repaid on September 4, 2025.
• A $250,000 related party working capital loan (issued August 20, 2024), a $93,633 loan to Hunniwell for travel expenses, and a $187,190 loan to Daniel Teo for severance were under the same terms as Senior Secured Notes and repaid on September 9, 2025.
• Loans of $425,000 and $450,000 were borrowed from Fang Family Fund I, LLC in July and August 2025, bearing 6% interest, and repaid on September 4, 2025.

Stakeholder Impact

• Shareholders experienced significant dilution due to the conversion of preferred stock and convertible notes into common shares, increasing outstanding shares from 9.3 million to 73.7 million. However, the IPO provided capital and a public market for the stock, and the conversion eliminated substantial debt and preferred equity, improving the balance sheet. The ongoing operating losses and 'going concern' warning indicate continued risk.
• Employees saw a decrease in research and development personnel, contributing to reduced R&D expenses. Stock-based compensation is a component of employee compensation. The company's ability to raise capital impacts job security and growth opportunities.
• Customers can expect continued development of next-generation TAH systems aimed at improving clinical outcomes, usability, and patient quality of life. The planned expansion into China could broaden access to the SynCardia TAH.
• Creditors benefited from the conversion of convertible notes and repayment of related party loans, which significantly reduced current liabilities, improving the company's short-term credit profile.
• Suppliers are impacted by the company's ability to scale operations and manage inventory, which influences its relationships and payment terms.

Next Steps

• Scale up product and rental revenue to offset fixed overhead costs.
• Invest heavily in the development of updates and next-generation devices, including a portable driver, hospital driver, and fully implantable system.
• Expand the patent portfolio to protect new technology.
• Establish sales, marketing, and distribution capabilities for the total artificial heart system, including additional inventory and expansion of the driver base.
• Remediate material weaknesses in internal control over financial reporting, including retaining additional accounting personnel, implementing multiple-level reviews, developing formal policies, and improving communication/monitoring of related party transactions.
• Proceed with the planned investment in SynCardia Medical (Beijing), Inc. for a 60% ownership interest when international and market conditions stabilize and are supportive.
• Continue to seek additional debt and/or equity financing to fund operations until positive cash flows are generated.

Key Dates

Recommendation

While the successful IPO and the conversion of significant debt and preferred stock into equity are positive developments that have substantially improved the company's balance sheet and liquidity, the underlying operational performance remains weak. The company reported an 86% increase in net loss and a 148% increase in gross loss for the nine months ended September 30, 2025, indicating a deteriorating core profitability. The 'going concern' warning, even after the capital raise, highlights the continued need for substantial revenue growth or further financing. The persistent material weaknesses in internal controls also present a governance risk. Given the recent IPO and the significant balance sheet restructuring, a 'hold' recommendation is appropriate. Investors should monitor the company's progress in scaling revenue, improving operational efficiency, and remediating internal control issues before considering further investment, as the long-term viability still faces significant challenges despite the recent capital infusion.

Keywords

Medical Devices, Artificial Heart, SynCardia TAH, Cardiovascular, IPO, SEC Filing, Financial Results, Biotechnology, Healthcare, Medical Technology, Going Concern, Internal Controls, Convertible Notes, Equity Financing, Patents